Prajapati, Vimal

Medical Oncology

Clinical Assistant Professor

Biography

Dr. Prajapati is a Clinical Assistant Professor at the University of Calgary, Department of Oncology.

Dr. Prajapati completed his Internal Medicine Residency at the University of Saskatoon, Saskatchewan and his Hematology residency at the University of Calgary.  He received his Royal College of Physicians and Surgeons of Canada fellowship in Hematology in November of 2018.

Dr. Prajapati commenced his appointment as a hematologist in Central Zone, Central Alberta Cancer Centre in Red Deer in the summer of 2018.   He also has his professional practice for benign related hematological conditions in Red Deer.

Dr. Prajapati has received numerous academic awards, including Jr Resident of the Year.  He has   completed research projects; having a keen interest in hematological methods of care in the settings of emergency departments, and further interest in quality assessment and improvement projects.

Dr. Prajapati is dedicated to developing the working team environment and enhanced care for patients. He   provides educational learning sessions for health care professionals on hematology topics.

The University of Alberta and University of Calgary have established in the Central Zone, the Rural Family Medicine and Internal Medicine Program for medical residents to take electives in this setting.  Dr. Prajapati provides one on one teaching and ambulatory experience for these residents in both his benign and cancer clinics.

Area of Focus

Summary of Research

  • Klil-Drori, Adi J., Prajapati D, Liang Z, Wang M, Toupin D, Alothman L, Lang E,  Suryanarayan D, Tagalakis V. Confirmation and Treatment).” “External Validation of ASPECT (Algorithm for Suspected Pulmonary Embolism. Medical Care 57(8):347-e52, August 2019   PMID: 30608277   https://doi.org/10.1097/MLR.0000000000001055.
  • Lee, H, McCulloch S, Mahe E, Shafey M, Rashid-Kolvear F, Khan F, Prajapati D, Neri P, Duggan P, Tay J, Bahlis N, Jimenez-Zepeda V.  Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-postive smouldering myeloma and polycythaemia vera.  Br J Haematol.  2020 Feb 20.. doi: 1111/bjh. 16533  PMID: 32080835 

Area Of Focus

Summary Of Research

  • Klil-Drori, Adi J., Prajapati D, Liang Z, Wang M, Toupin D, Alothman L, Lang E,  Suryanarayan D, Tagalakis V. Confirmation and Treatment).” “External Validation of ASPECT (Algorithm for Suspected Pulmonary Embolism. Medical Care 57(8):347-e52, August 2019   PMID: 30608277   https://doi.org/10.1097/MLR.0000000000001055.
  • Lee, H, McCulloch S, Mahe E, Shafey M, Rashid-Kolvear F, Khan F, Prajapati D, Neri P, Duggan P, Tay J, Bahlis N, Jimenez-Zepeda V.  Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-postive smouldering myeloma and polycythaemia vera.  Br J Haematol.  2020 Feb 20.. doi: 1111/bjh. 16533  PMID: 32080835